ALS Disease Model Service
Amyotrophic Lateral Sclerosis
Pre-clinicalActive
Key Facts
About NeuroProof
NeuroProof is a neuroscience-focused CRO based in Göttingen, Germany, offering specialized pre-clinical screening services. Its core platform combines Microelectrode Array (MEA) recordings of neuronal network activity with advanced data analysis and pattern recognition to model neurological diseases and assess compound effects. The company serves pharmaceutical and biotech clients by providing phenotypic assays, neurotoxicity evaluations, and custom disease models, primarily using iPSC-derived neurons, to accelerate CNS drug development and reduce reliance on animal testing.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Cell Therapy for ALS | INCELL | Unknown |
| ALS Research | GliaPharm | Research |
| ALS Biomarker Program | Linus Biotechnology | Pre-clinical |
| ALS Research (post-RADICAVA) | Tanabe Pharma America | Preclinical/Research |
| ALS Program | Biorchestra | Preclinical |
| Program(s) for ALS | AviadoBio | Pre-clinical |
| TCD601 for ALS | ITB Med | Phase 2 |
| ILB® for ALS | TikoMed | Phase 2 |
| ALS Patient-Led Research Initiative | BGI | Research |
| ALS Pathway Discovery | Anima Biotech | Preclinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |